Key result
Multimodality cardiac imaging enables early diagnosis, risk stratification, and treatment monitoring in cardiac amyloidosis.
Why the study?
Early diagnosis is crucial for cardiac amyloidosis because treatment efficacy and clinical outcomes depend on the stage of cardiac involvement, making multimodality imaging central to diagnosis, risk stratification, and monitoring.
Multimodality imaging, particularly quantitative techniques like extracellular volume mapping, is transitioning from descriptive findings to clinically actionable tools for diagnosing, risk-stratifying, and monitoring treatment response in cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Supports multimodality imaging integration in cardiac amyloidosis care; leaves open prospective validation of quantitative techniques for outcome impact.
Sclafani et al. (2026) conducted a review in Cardiac amyloidosis. Multimodality cardiac imaging was evaluated. Multimodality cardiac imaging, including echocardiography, bone scintigraphy, and cardiovascular magnetic resonance, plays a central role in the early diagnosis, risk stratification, and evaluation of treatment efficacy in cardiac amyloidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: